Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 12.37 -6.71% -0.89
STML closed down 6.71 percent on Friday, March 22, 2019, on 77 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical STML trend table...

Date Alert Name Type % Chg
Mar 22 Wide Bands Range Expansion 0.00%
Mar 21 Stochastic Reached Overbought Strength -6.71%
Mar 21 Wide Bands Range Expansion -6.71%
Mar 21 Overbought Stochastic Strength -6.71%
Mar 20 NR7 Range Contraction -4.85%
Mar 20 Wide Bands Range Expansion -4.85%
Mar 20 Overbought Stochastic Strength -4.85%
Mar 19 Overbought Stochastic Strength -7.41%
Mar 18 Stochastic Sell Signal Bearish -4.11%
Mar 18 Upper Bollinger Band Walk Strength -4.11%

Older signals for STML ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Biopharmaceutical Cancer Biology Stem Cells Tumor Platform Technology Refractory Acute Myeloid Leukemia Cancer Stem Cell Carcinogenesis Cancer Stem Cells
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.55
52 Week Low 7.82
Average Volume 771,186
200-Day Moving Average 13.8501
50-Day Moving Average 11.3468
20-Day Moving Average 12.2035
10-Day Moving Average 12.945
Average True Range 0.7509
ADX 18.85
+DI 23.7297
-DI 22.0602
Chandelier Exit (Long, 3 ATRs ) 11.5573
Chandelier Exit (Short, 3 ATRs ) 12.8227
Upper Bollinger Band 14.0715
Lower Bollinger Band 10.3355
Percent B (%b) 0.54
BandWidth 30.614168
MACD Line 0.5082
MACD Signal Line 0.4849
MACD Histogram 0.0233
Fundamentals Value
Market Cap 290.13 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -5.01
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.92
Resistance 3 (R3) 14.08 13.73 13.66
Resistance 2 (R2) 13.73 13.34 13.65 13.57
Resistance 1 (R1) 13.05 13.09 12.88 12.89 13.49
Pivot Point 12.70 12.70 12.61 12.62 12.70
Support 1 (S1) 12.02 12.31 11.85 11.86 11.25
Support 2 (S2) 11.67 12.06 11.59 11.17
Support 3 (S3) 10.99 11.67 11.08
Support 4 (S4) 10.83